Sareum Holdings plc (AIM:SAR)

Market Cap	24.54M +18.5%
Revenue (ttm)	n/a
Net Income	-4.93M
EPS	-0.04
Shares Out	163.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	706,949
Open	14.25
Previous Close	14.75
Day's Range	14.00 - 15.00
52-Week Range	11.75 - 40.00
Beta	-0.54
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 2, 2026

About Sareum Holdings

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-stage oral, selective Chk 1 inhibitor, which has completed Phase II clinic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 5
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: SAR

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error